MAPT and Alzheimer disease: In mouse experiments, 8 weeks of LYC treatment (5 mg/kg) reduced tau hyperphosphorylation at AD‐related sites by reversing the increase in malondialdehyde (MDA) levels and decrease in GSH peroxidase (GSH‐Px) levels in the serum of tau transgenic mice with a P301 L mutation.